Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rivaroxaban

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    122 result(s) found for: Rivaroxaban. Displaying page 3 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2020-000334-17 Sponsor Protocol Number: TRACK_001 Start Date*: 2023-03-31
    Sponsor Name:The George Institute of Global Health
    Full Title: Treatment of cardiovascular disease with low Rivaroxaban in Advanced Chronic Kidney Disease - TRACK trial
    Medical condition: Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004539-30 Sponsor Protocol Number: BAY59-7939/14373 Start Date*: 2012-10-23
    Sponsor Name:Bayer AG
    Full Title: 30-day, single-arm study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children with various manifestations of venous thrombosis
    Medical condition: venous thrombosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002345-38 Sponsor Protocol Number: 12/0033/CTU/IMM/001 Start Date*: 2012-10-30
    Sponsor Name:University College London
    Full Title: A prospective randomised controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.
    Medical condition: Patients with antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10002817 Antiphospholipid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004909-33 Sponsor Protocol Number: LCTU122 Start Date*: 2015-09-21
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: Thrombin Inhibition Preoperatively in Early Breast Cancer
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-022846-26 Sponsor Protocol Number: 1015 Start Date*: 2010-11-08
    Sponsor Name:University Hospital of Grenoble
    Full Title: Réversion de l'effet anticoagulant des nouveaux antithrombotiques anti Xa et anti IIa par des médicaments hémostatiques spécifiques ou non spécifiques : étude ex vivo chez le volontaire sain.
    Medical condition: volontaires sains
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006189-19 Sponsor Protocol Number: NL2021-13291 Start Date*: 2022-01-12
    Sponsor Name:Radboudumc
    Full Title: Trained immunity by dual-pathway inhibition (low-dose rivaroxaban and acetylsalicylic acid) in coronary artery disease
    Medical condition: coronary artery disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004507-13 Sponsor Protocol Number: ANT-006 Start Date*: 2021-03-02
    Sponsor Name:Anthos Therapeutics
    Full Title: A Multicenter, Randomized, Active-Controlled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared with Open-Label Rivaroxaban in Patients with Atrial F...
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001491-11 Sponsor Protocol Number: RIVAROXAFL3003 Start Date*: 2013-05-03
    Sponsor Name:Janssen-Cilag International NV
    Full Title: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial ...
    Medical condition: Prevention of stroke and non-CNS systemic embolism in patients with nonvalvular atrial fibrillation who undergo percutaneous coronary intervention
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) SE (Completed) IT (Completed) NL (Completed) DK (Completed) PL (Completed) BG (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-002234-39 Sponsor Protocol Number: BAY59-7939/15693 Start Date*: 2012-08-07
    Sponsor Name:Bayer HealthCare AG
    Full Title: A prospective, randomized, open-label, parallel-group, active-controlled, multicenter study exploring the efficacy and safety of once-daily oral rivaroxaban (BAY 59-7939) compared with that of dose...
    Medical condition: prevention of stroke and non-central nervous system systemic embolism in subjects with non-valvular atrial fibrillation scheduled for cardioversion
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) PT (Completed) ES (Completed) NL (Completed) DE (Completed) GR (Completed) BE (Completed) GB (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-001777-33 Sponsor Protocol Number: EARTH-TAVR01 Start Date*: 2016-09-01
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: EVALUATION OF CEREBRAL THROMBOEMBOLISM AFTER TAVR
    Medical condition: Patients with severe aortic stenosis that require Transcatheter aortic valve replacement are at risk for stroke. This study is to evaluate the occurrence and extent of cerebral embolization (total...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10002916 Aortic valve replacement PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001567-20 Sponsor Protocol Number: P161102J Start Date*: 2017-12-18
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Assessment of Dual antiplatelet therapy versus Rivaroxaban In atrial Fibrillation patients Treated with left atrial appendage closure: The randomized ADRIFT Study
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005395-35 Sponsor Protocol Number: GatesMRI-COD-01-T01-01 Start Date*: 2020-12-16
    Sponsor Name:Bill & Melinda Gates Medical Research Institute
    Full Title: A randomized, controlled, Phase 2b study to evaluate safety and efficacy of rivaroxaban (Xarelto®) for high risk people with mild COVID-19
    Medical condition: Mild COVID-19 in people who are at high risk for moderate or severe disease due to age, body mass index (BMI) and comorbidities, many of which are also thrombotic risks.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-005162-29 Sponsor Protocol Number: RivaSVT100 Start Date*: Information not available in EudraCT
    Sponsor Name:A.O. OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI
    Full Title: Treatment of portal, mesenteric, and splenic vein thrombosis with rivaroxaban. A pilot, prospective cohort study
    Medical condition: Portal, mesenteric, and splenic vein thrombosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004866 10043642 Thrombosis venous deep LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000981-70 Sponsor Protocol Number: 1408143 Start Date*: 2016-03-08
    Sponsor Name:Centre Hospitalier Universitaire de Saint-Etienne
    Full Title: A multicentre, randomised, double-blind, controlled, phase IIIb study to assess the efficacy and safety of Rivaroxaban 10mg od versus Enoxaparin 4000 IU for VTE PROphylaxis in NOn Major Orthopaedic...
    Medical condition: Venous Thromboembolism Prophylaxis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) CZ (Completed) NL (Completed) DE (Completed) GR (Completed) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-001484-79 Sponsor Protocol Number: RIVAROXAFL3002 Start Date*: 2013-02-06
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Open-label, Active-controlled Multi-center Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation
    Medical condition: Prevention of stroke and non-CNS systemic embolism in patients with nonvalvular atrial fibrillation who undergo catheter ablation
    Disease: Version SOC Term Classification Code Term Level
    16.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002282-33 Sponsor Protocol Number: COVID-PREVENT Start Date*: 2020-10-01
    Sponsor Name:Charité - Universitaetsmedizin Berlin
    Full Title: Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT)
    Medical condition: Patients with moderate to severe COVID-19 disease which may cause acute cardiac injury
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001630-21 Sponsor Protocol Number: BAY59-7939/39039039STM4001/18262 Start Date*: 2015-12-15
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
    Medical condition: Venous thromboembolism (VTE)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) CZ (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002105-18 Sponsor Protocol Number: 333336666666666699 Start Date*: 2017-05-04
    Sponsor Name:Helsinki City Hospital Haartman
    Full Title: Laboratory measurement of direct oral anticoagulants on patients with atrial fibrillation
    Medical condition: Non-valvular atrial fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004266-26 Sponsor Protocol Number: RIVAROXACS2002 Start Date*: 2015-04-13
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban versus Acetylsalicylic Acid in Addition to Either Clopidogrel or ...
    Medical condition: Acute Coronary Syndrome (ACS)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) CZ (Completed) NL (Completed) HU (Completed) ES (Completed) IT (Completed) BG (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-001094-58 Sponsor Protocol Number: BAY 59-7939 / 15572 Start Date*: 2011-09-13
    Sponsor Name:Bayer HealthCare AG
    Full Title: Prospective, multi-center, randomized, heparin-controlled dose-finding trial to evaluate the efficacy and safety of rivaroxaban, a direct factor Xa inhibitor, on the background of standard dual ant...
    Medical condition: Symptomatic CAD patients due to undergo an elective (non emergent) Percutaneous Coronary Intervention (PCI) on one or two lesions in the native coronary vessel(s).
    Disease: Version SOC Term Classification Code Term Level
    13.1 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 12:48:16 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA